PATENT CLAIM ANALYSIS

Application Number: 16172960
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["424", "197110"]

Abstract:
The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria  Neisseria meningitidis.  The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from  Neisseria meningitidis  serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of  N. meningitidis  strains in children as well as adults.

Claim (Index 18):
A method of vaccinating a human susceptible to infection due to  Neisseria meningitidis  comprising administering to the human an immunologically effective amount of an immunological composition comprising a mixture of four distinct and separately made protein-capsular polysaccharide conjugates, wherein the first conjugate comprises purified  N. meningitidis  capsular polysaccharide of serogroup W-135 conjugated to a purified carrier protein, the second conjugate comprises purified  N. meningitidis  capsular polysaccharide of serogroup Y conjugated to a purified carrier protein, the third conjugate comprises purified  N. meningitidis  capsular polysaccharide of serogroup A conjugated to a purified carrier protein, and the fourth conjugate comprises purified  N. meningitidis  capsular polysaccharide of serogroup C conjugated to a purified carrier protein, wherein the immunological composition has the capacity to elicit in children less than two years of age a primary serum IgG response and a serum bactericidal antibody response to each of the  N. meningitidis  serogroups A, C, W-135 and Y capsular polysaccharides, wherein said serum bactericidal antibody response is higher than that elicited by the licensed, unconjugated, tetravalent A, C, W-135 and Y meningococcal capsular polysaccharide vaccine.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 97.0
- Lexical Diversity: 1.41176
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14636870', '13843037', '10054638', '14257551', '13738698']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.763757806616727
- 35 USC 102 Novelty (BERT): 0.6387125439029833
- Combined Prediction Score: 0.7512532803453525
- Mean Citation Score: 582.529948
- Max Citation Score: 583.8678
- Similarity Product: 579.4348537652851

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test